MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds

thought leadership

Trends 2024: Will GLP-1 receptor agonists dominate the MASH therapeutic market?


Amidst a growing prevalence of fatty liver diseases, hepatology experts explore the latest developments in the area, including nomenclature changes, therapeutic advancements of GLP-1 and MASH-specific drugs, and the potential benefits of more integrated care.

The field of hepatology has recently undergone some significant changes. A rethinking of how fatty liver diseases are named and categorized, and the arrival of obesity- and diabetes-targeting GLP-1 receptor agonists for treating associated comorbidities, have raised some important questions on the future of treatment for these diseases. Recently, faculty members from the International Hepatology Education Program (IHEP) met to discuss these changes and how they could impact the patient treatment journey and future drug development programs for liver diseases, previously named “fatty liver” diseases.

An urgent imperative in the landscape.

Closely linked to the global epidemic of obesity and type 2 diabetes, fatty liver disease attributed to metabolic dysfunction is becoming more prevalent and severe. Despite ongoing research efforts, there are no approved therapies tailored specifically for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. This highlights the urgent need for effective treatments that can slow or reverse disease progression. However, tailoring treatments to individual profiles remains challenging due to varying disease severity and associated comorbidities.

Navigating complex regulatory pathways, exploring potential combination therapies, ensuring long-term safety, and promoting patient access all contribute to the comprehensive approach required to combat these diseases. As a first step, however, increasing awareness and an accurate understanding of the disease is crucial for enhancing both the patient experience and treatment options.

Read on for expert insights from clinical experts on:

  • How new nomenclature and categorization connects fatty liver disease and metabolic conditions
  • GLP-1 receptor agonist use in obesity, diabetes, and MASH
  • The impact of GLP-1s on MASH clinical trials
  • Potential benefits of more integrated care in this therapy area
  • The future for the management of MASH

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement


Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.